

Tuberculosis profile: Slovenia

Population 2021: 2.1 million

Estimates of TB burden*, 2021

	Number	(Rate per 100 000 population)
Total TB incidence	91 (78-100)	4.3 (3.7-5)
HIV-positive TB incidence	0 (0-2)	0 (0-0.1)
MDR/RR-TB incidence**	1 (0-1)	0.03 (0-0.06)
HIV-negative TB mortality	14 (14-15)	0.68 (0.67-0.69)
HIV-positive TB mortality	0 (0-1)	0.01 (0-0.05)

Estimated proportion of TB cases with MDR/RR-TB*, 2021

New cases	0.53% (0.17-1.1)
Previously treated cases	3.1% (0.46-9.7)

Universal health coverage and social protection*

TB treatment coverage (notified/estimated incidence), 2021	87% (75-100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2021	17% (14-19)

TB case notifications, 2021

Total new and relapse	79
- % tested with rapid diagnostics at time of diagnosis	86%
- % with known HIV status	85%
- % pulmonary	85%
- % bacteriologically confirmed [^]	96%
- % children aged 0-14 years	2%
- % women (aged ≥15 years)	41%
- % men (aged ≥15 years)	57%
Total cases notified	80

TB/HIV care in new and relapse TB patients, 2021

	Number	(%)
Patients with known HIV status who are HIV-positive	0	0%
- on antiretroviral therapy	0	

Drug-resistant TB care**, 2021

% of bacteriologically confirmed TB cases tested for rifampicin resistance - New cases [^]	98%
% of bacteriologically confirmed TB cases tested for rifampicin resistance - Previously treated cases [^]	100%
Laboratory-confirmed cases - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^{^^}	1
Patients started on treatment - MDR/RR-TB (without pre-XDR-TB/XDR-TB) ^{^^^}	1
Laboratory-confirmed cases - pre-XDR-TB or XDR-TB ^{^^}	0
Patients started on treatment - pre-XDR-TB or XDR-TB ^{^^^}	0
MDR/RR-TB cases tested for resistance to any fluoroquinolone	1

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2020	74%	74
Previously treated cases, excluding relapse, registered in 2020	50%	2
HIV-positive TB cases registered in 2020		0
MDR/RR-TB cases started on second-line treatment in 2019		
Pre-XDR-TB/XDR-TB cases started on second-line treatment in 2019		

TB preventive treatment, 2021

% of HIV-positive people (newly enrolled in care) on preventive treatment	
% of children (aged < 5 years) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100% (100-100)

* Estimates of TB burden are produced by WHO in consultation with countries. Ranges represent uncertainty intervals.

** RR is TB resistant to rifampicin (R); MDR is TB resistant to R + isoniazid; pre-XDR is TB resistant to R + any fluoroquinolone


[^] Calculated for pulmonary cases only

^{^^} Includes cases with unknown previous TB treatment history

^{^^^} Includes patients diagnosed before 2021 and patients who were not laboratory-confirmed


Incidence, New and relapse TB cases notified, HIV-positive TB incidence

(Rate per 100 000 population per year)




HIV-negative TB mortality

(Rate per 100 000 population per year)



Incidence, Notified cases by age group and sex, 2021

(Number)



Cases attributable to five risk factors, 2021

(Number)

